LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is diversifying its treasury by purchasing cryptocurrencies, specifically 10.5 Bitcoin and 300 Ethereum, totaling approximately $2.6 million, which now constitutes about 43.6% of its treasury holdings [2][3]. Group 1: Cryptocurrency Strategy - The company has received approval from its Board of Directors to increase its cryptocurrency allocation to up to 50% of its treasury [2]. - The addition of Bitcoin and Ethereum is part of a strategy to build a balanced digital asset portfolio that complements cash holdings [3]. - The company aims to enhance its adaptability and long-term growth in the digital economy through this diversification [3]. Group 2: Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing new cancer therapies, particularly its lead compound, LB-100, which has shown promise in enhancing chemotherapy and immunotherapy outcomes [4][5]. - The company is engaged in pioneering research in cancer biology, specifically in the area of activation lethality, and is currently conducting proof-of-concept clinical trials for various cancer types [5].